Zacks Investment ResearchThu, 07 May 2026 17:50:13 GMTRVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense ViewRVMD+1.09%
Seeking AlphaThu, 07 May 2026 09:41:14 GMTRevolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call TranscriptRVMD+1.09%
Investors Business DailyThu, 30 Apr 2026 12:00:48 GMTWhy This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer ResultsRVMD+1.09%
WSJTue, 28 Apr 2026 09:30:00 GMTThere's a Revolution in Cancer. But Can Big Pharma Afford It?RVMD+1.09%
The Motley FoolMon, 27 Apr 2026 15:00:00 GMTRevolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It SeemsRVMD+1.09%
BenzingaFri, 17 Apr 2026 11:37:42 GMTTop 2 Health Care Stocks That May Fall Off A Cliff In Q2RVMD+1.09%
ForbesWed, 15 Apr 2026 16:10:15 GMTThis Pill May Help Pancreatic Cancer Patients Live LongerRVMD+1.09%
Seeking AlphaTue, 14 Apr 2026 19:18:01 GMTRevolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions UnderwayRVMD+1.09%
Zacks Investment ResearchTue, 14 Apr 2026 17:35:18 GMTRVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer DataRVMD+1.09%
InvezzMon, 13 Apr 2026 14:13:43 GMTRevolution Medicines surges 38% as pancreatic cancer drug shows breakthroughRVMD+1.09%
BenzingaMon, 13 Apr 2026 14:10:50 GMTRevolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus ChemoRVMD+1.09%
CNBC TelevisionMon, 13 Apr 2026 13:45:00 GMTRevolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trialRVMD+1.09%
BarronsMon, 13 Apr 2026 13:11:00 GMTThis Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success.RVMD+1.09%
CNBCMon, 13 Apr 2026 12:00:19 GMTRevolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trialRVMD+1.09%
CNBCFri, 10 Apr 2026 17:49:43 GMTFormer Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancerRVMD+1.09%
24/7 Wall StreetWed, 01 Apr 2026 11:35:58 GMTThese 5 Biotechs Could Be the Next Big GLP-1 Acquisition TargetRVMD+1.09%
Zacks Investment ResearchFri, 27 Mar 2026 16:31:19 GMTRevolution Medicines (RVMD) Down 8.8% Since Last Earnings Report: Can It Rebound?RVMD+1.09%
Seeking AlphaTue, 03 Mar 2026 16:52:13 GMTRevolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference TranscriptRVMD+1.09%
Zacks Investment ResearchThu, 26 Feb 2026 15:41:22 GMTRVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense ViewRVMD+1.09%
Seeking AlphaThu, 26 Feb 2026 02:17:48 GMTRevolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call TranscriptRVMD+1.09%